Harmony Biosciences Holdings (HRMY) Free Cash Flow (2019 - 2026)

Harmony Biosciences Holdings has disclosed Free Cash Flow across 8 years of filings, most recently posting $27.8 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at $27.8 million, down 18.01% year-over-year; the trailing twelve-month figure through Mar 2026 was $341.8 million (up 54.38% YoY), and the FY2025 annual result was $347.9 million, up 59.09% from the prior year.
• Free Cash Flow came in at $27.8 million for Q1 2026 at Harmony Biosciences Holdings, down from $126.0 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $126.0 million in Q4 2025 to a low of $26.7 million in Q4 2022.
• The 5-year median for Free Cash Flow is $42.6 million (2023), against an average of $56.3 million.
• Across the five-year window, Free Cash Flow retreated 28.92% in 2022 and soared 186.97% in 2023, its largest moves.
• Harmony Biosciences Holdings' Free Cash Flow stood at $26.7 million in 2022, then jumped by 186.97% to $76.6 million in 2023, then slipped by 1.97% to $75.0 million in 2024, then soared by 67.95% to $126.0 million in 2025, then tumbled by 77.98% to $27.8 million in 2026.
• The last three Free Cash Flow figures came in at $27.8 million (Q1 2026), $126.0 million (Q4 2025), and $108.7 million (Q3 2025), per Business Quant data.